Ep. 181 - Crosscurrents Titelbild

Ep. 181 - Crosscurrents

Ep. 181 - Crosscurrents

Jetzt kostenlos hören, ohne Abo

Details anzeigen

Über diesen Titel

 In this episode of the Investor Professor Podcast, we wrap up January with a clear-eyed look at how the major indexes and sectors kicked off the year, highlighting early leadership from defensives, cyclicals, and industrials while technology, financials, and healthcare lagged. The discussion breaks down key earnings from Apple, Microsoft, Meta, and Tesla, revealing a growing market rotation tied to AI spending, margins, and monetization. With investors increasingly focused on returns rather than hype, the episode explores why capital is shifting from high-flying tech into companies positioned to profit from the AI buildout regardless of who ultimately wins.

The episode also tackles policy and political crosscurrents, including Trump’s nomination of a new Fed Chair and proposed credit card rate caps, and how headline risk can create long-term buying opportunities. Listeners are introduced to under-the-radar companies like KLA Corp., a critical quality-control player in the semiconductor ecosystem, alongside practical portfolio takeaways centered on watchlists, patience, and disciplined investing. As earnings season rolls on, the message is clear: volatility creates opportunity—if you’ve done the homework.

*This podcast contains general information that may not be suitable for everyone. The information contained herein should not be construed as personalized investment advice. There is no guarantee that the views and opinions expressed in this podcast will come to pass. Investing in the stock market involves gains and losses and may not be suitable for all investors. Information presented herein is subject to change without notice and should not be considered as a solicitation to buy or sell any security. Rydar Equities, Inc. does not offer legal or tax advice. Please consult the appropriate professional regarding your individual circumstance. Past performance is no guarantee of future results.
Noch keine Rezensionen vorhanden